+

WO2006069079A3 - Methods and formulations - Google Patents

Methods and formulations Download PDF

Info

Publication number
WO2006069079A3
WO2006069079A3 PCT/US2005/046204 US2005046204W WO2006069079A3 WO 2006069079 A3 WO2006069079 A3 WO 2006069079A3 US 2005046204 W US2005046204 W US 2005046204W WO 2006069079 A3 WO2006069079 A3 WO 2006069079A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
methods
prevention
present
receptor antagonists
Prior art date
Application number
PCT/US2005/046204
Other languages
French (fr)
Other versions
WO2006069079A2 (en
Inventor
Simon M Blake
William Henry Miller
Amyn Sayani
H Jeffrey Wilkens
Original Assignee
Smithkline Beecham Corp
Simon M Blake
William Henry Miller
Amyn Sayani
H Jeffrey Wilkens
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Simon M Blake, William Henry Miller, Amyn Sayani, H Jeffrey Wilkens filed Critical Smithkline Beecham Corp
Priority to JP2007548398A priority Critical patent/JP2008524334A/en
Priority to EP05854851A priority patent/EP1841406A4/en
Publication of WO2006069079A2 publication Critical patent/WO2006069079A2/en
Publication of WO2006069079A3 publication Critical patent/WO2006069079A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention describes methods and formulations using vitronectin receptor antagonists for the prevention of excessive scarring.
PCT/US2005/046204 2004-12-21 2005-12-20 Methods and formulations WO2006069079A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2007548398A JP2008524334A (en) 2004-12-21 2005-12-20 Methods and prescriptions
EP05854851A EP1841406A4 (en) 2004-12-21 2005-12-20 Methods and formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63782404P 2004-12-21 2004-12-21
US60/637,824 2004-12-21

Publications (2)

Publication Number Publication Date
WO2006069079A2 WO2006069079A2 (en) 2006-06-29
WO2006069079A3 true WO2006069079A3 (en) 2007-04-19

Family

ID=36602271

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/046204 WO2006069079A2 (en) 2004-12-21 2005-12-20 Methods and formulations

Country Status (6)

Country Link
EP (1) EP1841406A4 (en)
JP (1) JP2008524334A (en)
AR (1) AR052823A1 (en)
PE (1) PE20060870A1 (en)
TW (1) TW200635902A (en)
WO (1) WO2006069079A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232308B1 (en) * 1999-02-03 2001-05-15 Merck & Co., Inc. Bezazepine derivatives as αv integrin receptor antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60311C2 (en) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Vitronectin receptor antagonists
UA71586C2 (en) * 1998-12-04 2004-12-15 Smithkline Beecham Corp A vitronectin receptor antagonist
AU2002305164B2 (en) * 2001-04-10 2005-07-28 Smithkline Beecham Corporation Method of inhibiting adhesion formation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232308B1 (en) * 1999-02-03 2001-05-15 Merck & Co., Inc. Bezazepine derivatives as αv integrin receptor antagonists

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KOYAMA S. ET AL.: "Tranilast inhibits protein kinase C-dependent signaling pathway linked to angiogenic activities and gene expression of retinal micropapillary endothelial cells", BRITISH JOURNAL OF PHARMACOLOGY, vol. 127, 1999, pages 537 - 545, XP003010728 *
NAKAMURA K. ET AL: "Factors affecting hypertrophic scar development in median sternotomy incisions for congenital cardiac surgery", J. AM. COLL. SURG., vol. 185, no. 3, September 1997 (1997-09-01), pages 218 - 223, XP008079023 *
NELSEN-SALZ B. ET AL.: "Integrin (alpha-v-beta-3)(vitronectin receptor) is a candidate receptor for virulent echovirus 9 strain Barty", JOURNAL OF GENERAL VIROLOGY, vol. 80, 1999, pages 2311 - 2313, XP002407940 *
See also references of EP1841406A4 *
THEORET C.L.: "Expression of TGF-B1, TGF-B3 and bFGF in Full-Thickness Dermal Wounds of the Horse", 2000, NAT'L LIBRARY OF CANADA, ACQUISITIONS AND BIBLIOGRAPHIC SERVICES, 395 WELLINGTON STREET OTTAWA, ON K1A 0N4 CANADA, pages: 1 - 171, XP003010727 *

Also Published As

Publication number Publication date
EP1841406A4 (en) 2008-06-25
PE20060870A1 (en) 2006-08-16
WO2006069079A2 (en) 2006-06-29
AR052823A1 (en) 2007-04-04
EP1841406A2 (en) 2007-10-10
TW200635902A (en) 2006-10-16
JP2008524334A (en) 2008-07-10

Similar Documents

Publication Publication Date Title
HRP20181459T1 (en) Humanized anti-beta7 antagonists and uses thererfor
WO2008127226A3 (en) P13 kinase antagonists
WO2006058236A3 (en) Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
IL245462A0 (en) Humanized anti-cmet antagonists
UA95768C2 (en) MUSCARIN ANTEGONYL ACETILON ANTAGONISTS
WO2005079756A3 (en) Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
HK1098464A1 (en) Chemokine receptor antagonists
IL175084A0 (en) Antagonists of the bradykinin b1 receptor
WO2005094251A3 (en) M3muscarinic acetylcholine receptor antagonists
IL178622A0 (en) Piperazinylpiperidine derivatives as chemokine receptor antagonists
AU2003255501A1 (en) Cxcr4 receptor antagonists
WO2005067537A3 (en) Muscarinic acetylcholine receptor antagonists
EP1747219A4 (en) Muscarinic acetylcholine receptor antagonists field of the invention
WO2006050239A3 (en) Muscarinic acetylcholine receptor antagonists
EP1677796A4 (en) Muscarinic acetylcholine receptor antagonists field of the invention
EP1751175A4 (en) Interleukin-1 receptor antagonists, compositions, and methods of treatment
WO2006106358A3 (en) Use of nk-3 receptor antagonists for the treatment of nausea and vomiting
WO2006005057A3 (en) Muscarinic acetylcholine receptor antagonists
EP1806147A4 (en) Use of immunesuppressant receptor
WO2006017768A3 (en) Muscarinic acetylcholine receptor antagonists
WO2005099706A3 (en) Muscarinic acetylcholine receptor antagonists
WO2006017767A3 (en) Muscarinic acetylcholine receptor antagonists
WO2006069079A3 (en) Methods and formulations
WO2008142483A3 (en) Vaccine compositions and methods of use thereof
WO2006010077A3 (en) Prodrugs of lonidamine and lonidamine analogs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007548398

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005854851

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005854851

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载